

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

Akt (pan) (11E7) Rabbit mAb

RRID:AB_2225340

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4685, RRID:AB_2225340

Antibody Information

URL: http://antibodyregistry.org/AB_2225340

Proper Citation: Cell Signaling Technology Cat# 4685, RRID:AB_2225340

Target Antigen: Akt2

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F. Consolidation on 10/2018: AB_10698888, AB_2225340.

Antibody Name: Akt (pan) (11E7) Rabbit mAb

Description: This monoclonal targets Akt2

Target Organism: rat, mouse, human

Antibody ID: AB_2225340

Vendor: Cell Signaling Technology

Catalog Number: 4685

Record Creation Time: 20250820T040704+0000

Record Last Update: 20250820T180518+0000

Ratings and Alerts

No rating or validation information has been found for Akt (pan) (11E7) Rabbit mAb.

No alerts have been found for Akt (pan) (11E7) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 167 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tang S, et al. (2026) PTEN Loss Promotes PI3K γ Phosphorylation and EPHA2/SRC/p-PI3K γ Y962 Complex Assembly to Drive Tumorigenesis. *Cancer discovery*, 16(3), 521.

Pang J, et al. (2026) Law-NQO1 redox boosts the pentose phosphate pathway to confer stem-like properties and antitumor durability in effector CD8⁺ T cells. *Cell chemical biology*, 33(3), 321.

Li E, et al. (2026) Oxytocin signaling in adipocytes is required for normal milk fat production. *Cell metabolism*, 38(6), 1141.

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. *Cancer research*, 86(5), 1194.

Shen Y, et al. (2026) CCL1-AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages. *Cancer immunology research*, 14(4), 676.

Zhou S, et al. (2026) NPC2 suppresses osteolytic metastasis in lung adenocarcinoma via the AKT/mTOR pathway and tumor-osteoclast crosstalk. *iScience*, 29(3), 115017.

Wang Y, et al. (2026) γ -Linolenic acid suppresses Th17 cell differentiation to mitigate allergic rhinitis by binding to Lyn kinase in mast cells. *British journal of pharmacology*, 183(12), 3234.

Tong Y, et al. (2026) A new form of diabetes caused by INS mutations defined by zygosity, stem cell and population data. *EMBO molecular medicine*, 18(2), 620.

Guo Q, et al. (2026) Human GBP4 promotes TRIM21-BIP-dependent autophagy to restrict *M. tuberculosis* infection by preventing SORT1-mediated progranulin degradation. *Cell reports*, 45(8), 117739.

Osorio-Vasquez V, et al. (2026) Patient-derived organoids reveal ductal dysfunction and CFTR-modulator responses in chronic pancreatitis. *Cell stem cell*.

Carta L, et al. (2026) Identification of Small-Molecule Inhibitors that Block the GTP-Binding Pocket of K-Ras and Other Members of the Ras Superfamily of Small GTPases. *Molecular cancer therapeutics*, 25(1), 84.

Zhang S, et al. (2026) A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. *Neuron*.

Ogawa M, et al. (2026) FGF21 suppresses hepatocellular carcinoma by driving competitive cell-cell interactions. *Cell reports*, 45(6), 117410.

Wang X, et al. (2025) Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor-Ligand Interactions That Instructs Intratumoral ??T-cell Activity. *Cancer research*, 85(2), 277.

Abdelhameed AM, et al. (2025) Adiponectin Receptor Agonist AdipoRon Ameliorates the Metabolic Complications in a Hyperandrogenic Rat Model of PCOS. *Endocrinology*, 167(1).

Zhou Z, et al. (2025) Muscle metabolic resilience and enhanced exercise adaptation by Esr1-induced remodeling of mitochondrial cristae-nucleoid architecture in males. *Cell reports. Medicine*, 6(5), 102116.

Tsai HC, et al. (2025) Acrolein induces exosomal miR-30a-5p/NCAM1 axis promoting glioma progression. *Molecular cancer therapeutics*.

Guo D, et al. (2025) OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth. *Molecular cell*, 85(4), 843.

Oyabu M, et al. (2025) Dnmt3a overexpression disrupts skeletal muscle homeostasis, promotes an aging-like phenotype, and reduces metabolic elasticity. *iScience*, 28(4), 112144.

Wu D, et al. (2025) Targeting IRE1? improves insulin sensitivity and thermogenesis and suppresses metabolically active adipose tissue macrophages in male obese mice. *eLife*, 13.